This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

David Z. J. Chu, MD; Joshua D. I. Ellenhorn, MD; I. Benjamin Paz, MD; Lawrence D. Wagman, MD; Wydell L. Williams, Jr, MD
Duarte, Calif

JAMA. 1994;271(5):345-346.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In their recently published article, Moertel et al¹ concluded that carcinoembryonic antigen (CEA) monitoring has questionable value in the postoperative management of colorectal cancer patients, and that routine determination of postoperative CEA levels is associated with significant expense, without benefit to the patient.

While it is important to question the utility of costly testing, we do not feel that the conclusions reached in the article are supported by the data presented. There was no standardized regimen of CEA testing or follow-up of results; the number of CEA levels measured per patient ranged from one to 39; it is unclear whether levels were measured prior to or only after clinical suspicion of metastatic disease; there was no standardized method of interpreting the CEA results or acting on those results, and no standardized protocol was established for evaluating elevated CEA results. In addition, it is probably inappropriate to . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?